Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial

OBJECTIVES: In the IMPACT trial (NCT02164513), triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) showed clinical benefit compared with dual therapy with either FF/VI or UMEC/VI in the treatment of chronic obstructive pulmonary disease (COPD). We used data from IMPACT to de...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabrio, Andrea, Gunsoy, Necdet B, Baio, Gianluca, Martin, Alan, Paly, Victoria F, Risebrough, Nancy, Halpin, David M G, Singh, Dave, Wise, Robert A, Han, MeiLan K, Martinez, Fernando J, Criner, Gerard J, Martin, Neil, Lipson, David A, Ismaila, Afisi S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338436/
https://www.ncbi.nlm.nih.gov/pubmed/35915738
http://dx.doi.org/10.2147/COPD.S342244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338436/
https://www.ncbi.nlm.nih.gov/pubmed/35915738
http://dx.doi.org/10.2147/COPD.S342244

Ejemplares similares